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Abstract  29 
 30 
To investigate the effects of subcutaneous detemir on glucose flux, lipid metabolism and 31 
brain function, twelve people with type 1 diabetes received in random order 0.5Units/kgBW 32 
detemir or NPH insulin. Glucose concentration was clamped at 5mmol/L then increased to 33 
10mmol/L. Glucose production rate (glucose Ra), glucose uptake (glucose Rd) and glycerol 34 
production (glycerol Ra) were measured with a constant iv infusion of  [6,62H2]glucose and 35 
[2H5]glycerol. Electroencephalography direct (DC) and alternating (AC) current potentials 36 
were measured. While detemir induced comparable effects on glucose Ra, glucose Rd and 37 
glycerol Ra during euglycaemia, compared with NPH, it triggered a distinct negative shift in 38 
DC-potentials, with significant treatment effect in frontal cerebrocortical channels (p<0.001). 39 
AC spectral power showed significant differences in theta and alpha frequencies during  40 
euglycaemia (p=0.03). Subcutaneous detemir exerts different effects on brain function when 41 
compared with NPH in people with type 1 diabetes.This may be an important mechanism 42 
behind the limitation of weight gain with detemir. 43 
  44 
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Introduction 47 
 48 
Exogenous insulin, as administered to people with type 1 diabetes, is frequently associated 49 
with weight gain or weight stability rather than weight loss. Detemir is associated with less 50 
weight gain compared with NPH insulin (1,2). Detemir may influence appetite and reduce 51 
energy intake through greater direct effects on the brain (1). Alternatively, it may have a 52 
higher action in liver than peripheral tissues and therefore a less anabolic effect on peripheral 53 
tissues (3) or result in a reduction in defensive snacking (4).  54 
 55 
 3 
This study aimed to delineate the important physiological action of clinically relevant 56 
subcutaneous doses of detemir compared with NPH insulin on glucose flux and lipolysis 57 
measured using stable isotope techniques and brain function measured by EEG DC-potentials 58 
and AC-potentials in people with type 1 diabetes.  59 
 60 
Methods 61 
 62 
This was an investigator led, double-blind crossover metabolic study for people with type 1 63 
diabetes. Participant inclusion is shown in supplement table1. 64 
 65 
Participants omitted their basal insulin the night before a metabolic study. At commencement 66 
they were transferred to a soluble variable rate insulin infusion (VRII) to maintain a blood 67 
glucose concentration of 5mmol/l. Primed (170mg) continuous infusion (1.7mg/min) of  68 
[6,6-2H2]glucose and 0.4mg/kg BW/min of [1,1,2,3.32H5]glycerol (Cambridge isotopes, CK 69 
Gas Products Ltd, UK) were administered from -120 min. At isotopic steady state, 70 
participants were given 0.5Units/kgBW of subcutaneous detemir or NPH insulin depending 71 
on randomisation order. The VRII was tailed off over 90 minutes and blood samples taken to 72 
measure glucose and glycerol concentration and enrichment and NEFA concentration at 73 
predetermined time points. A variable infusion rate of dextrose spiked with [6,6-2H2]glucose 74 
maintained blood glucose at 5mmol/l until 210minutes and then 10mmol/l until 300minutes. 75 
To prevent rapid changes in tracer to tracee ratio of glucose, 20% dextrose was spiked with 76 
4mg/g of [6,6-2H2]glucose tracer at the start of the euglycaemic and hyperglycaemic period. 77 
 78 
EEG recordings were taken using a portable recorder (SKU:M97130 Vitaport; Temec 79 
Instruments B.V. Netherlands). DC-potential recordings were obtained from frontal (F3,F4), 80 
frontocentral (FC3,FC4) and central (C3,C4) electrodes. AC-potentials were recorded from 81 
F3,F4,FC3,FC4 and occipital (01,02) electrodes. Each electrode was referenced to 82 
contralateral mastoid electrodes. The Karolinska Drowsiness Test was undertaken at 83 
 4 
predetermined time points (5). Participants were required to stare at a dot with their eyes open 84 
(3minutes) and stay immobile with their eyes closed (3minutes).  85 
 86 
Analytical Procedures 87 
 88 
Blood glucose concentrations were measured using a glucose analyser (YSI 2300 89 
Clandon Scientific, Yellow Springs Instruments, Ohio, USA). Plasma glucose concentrations 90 
were measured on a Cobas MIRA using ABX Pentra glucose kit (Horiba ABX, Northampton, 91 
UK), plasma glycerol concentrations using Randox glycerol kit and  plasma NEFA 92 
concentrations using a Randox Calorimetric kit (Randox Laboratories, Co.Antrim, UK)  93 
 94 
Isotopic enrichment of plasma glucose was determined as the trimethylsilyl-O-methyloxime 95 
derivative (6), using gas chromatography mass spectrometry (GC-MS) model 597S CMSD 96 
inertXL EI/CI MSD, Agilent Technologies, Berkshire, U.K. The isotopic enrichment of 97 
plasma glycerol was determined as the tert-butyltrimethylsilyl glycerol derivative (7) using  98 
GC-MS model 5973 network, Agilent Technologies, Berkshire, U.K. 99 
 100 
Glucose Ra and Rd and glycerol Ra were calculated using Steele’s non-steady state equations 101 
modified for stable isotopes (8). EEG data was exported as European Data Format (EDF) file 102 
and imported into ProFusion PSG3 (Compumedics Ltd, Abbotsford 3067, Australia).   103 
Median values for consecutive 5minute periods were referenced to 0V using the average 104 
voltage from insulin dosing.  105 
 106 
AC channels were re-exported from ProFusion as an EDF file with filtering applied. The EDF 107 
was then imported into Vitascore (TEMEC Instruments B.V. Spekhofstraat2, Netherlands). 108 
Using a 2second window and applying Fast Fourier Transform up to a frequency of 32Hz, 109 
giving a resolution of 0.5Hz spectral power (mV) was calculated for 8 frequency bands.  110 
 5 
Statistical Analysis 111 
 112 
Glucose Ra, glycerol Ra and glucose Rd data were subjected to two way ANOVA including 113 
treatment (detemir vs. NPH) and time as repeated measure. The Bonferroni method was used 114 
to correct for multiple comparisons. DC-potential and AC-potential data were subjected to 115 
two way and three way ANOVAs. Data are expressed as mean and standard errors of means 116 
(SEM) 117 
 118 
Results 119 
Twelve participants completed the metabolic study (8 females, 4 males). Mean age 33.5±4.7 120 
years, weight 70.0±2.5kg, BMI 24.5±0.8kg/m2, HbA1c 6.9±0.7%, diabetes duration 16.1±2.4 121 
years). Five used continuous subcutaneous insulin infusions. 122 
 123 
Glucose and Glycerol Metabolism 124 
 125 
The plasma glucose concentration profile for detemir and NPH insulin were similar. 126 
(euglycaemia p=0.30, hyperglycaemia p=0.61). Plasma glucose at isotopic equilibrium was 127 
6.9±0.4 mmol/l in the detemir group and 6.0±0.3 mmol/l in the NPH group (supplement fig1).  128 
 129 
Glucose Ra and glucose Rd were similar during the euglycemic period. During the 130 
hyperglycemic period glucose Rd was higher with NPH insulin than detemir (p=0.003) 131 
(supplement fig2). Glycerol Ra and NEFA concentrations were similar (P= 0.09). 132 
 133 
DC-potentials  134 
 135 
DC-potentials showed a greater negative shift in the detemir group than the NPH group 136 
(p=0.002) (Fig1). The data was then modelled to account for missing data, participant effects 137 
and periodicity. There was a significant treatment by channel interaction (p<0.001). Table 1 138 
 6 
shows the effect of treatment for each individual channel. There were significant treatment 139 
and treatment by time interactions for channels F3 and F4, during euglycaemia (supplement 140 
table2).  141 
 142 
AC- Spectral Power 143 
 144 
During ‘eyes-open’, combined channels showed treatment effects in the theta frequency band 145 
during euglycaemia (F(1,39)=4.87,p=0.03). The treatment interactions and treatment by 146 
channel interactions are presented in supplemental table3. Supplemental table4 demonstrates 147 
treatment by time interaction for each channel in the theta and alpha band. No significant 148 
treatment effects were obtained during ‘eyes-closed’. 149 
 150 
Discussion 151 
 152 
This is the first study to provide evidence that when compared with NPH insulin, clinically 153 
relevant doses of subcutaneous detemir may act differently in the brain. While, eliciting 154 
comparable effects on glucose flux and lipolysis during euglycaemia, detemir triggered a 155 
greater negative shift in DC-potentials. The negative shift was of a global nature, with the 156 
greatest effect in the frontal cerebrocortical regions.  157 
 158 
Interpretation during hyperglycaemia is difficult as the differences may result from increased 159 
rate of peripheral glucose uptake in the NPH group rather than a direct difference of insulin 160 
action in the brain. There were also differences in AC-potentials, with activation of theta and 161 
alpha activity in frontocentral cerebrocortical regions. The exact significance remains unclear.  162 
Although, we cannot determine the underlying molecular mechanism, the greater action of 163 
detemir in the brain may be related to its albumin binding or the novel method of protraction. 164 
The capillary endothelial barrier in peripheral tissue may limit the transfer of detemir from the 165 
 7 
circulation into the extravascular space. Detemir may also cross the blood brain barrier (BBB) 166 
more easily than human insulin (9), perhaps due detemir’s lipophilic property (10). 167 
Alternatively, there may be more unbound active detemir available to bind to the insulin 168 
receptor in the brain as albumin is very low in the cerebrospinal fluid. Finally, detemir could 169 
cross the BBB equally but have different binding affinities to the insulin receptors located 170 
within the brain. What is evident is that further work in the field is still required.  171 
 172 
This study does not identify what the changes are driving biologically. Hallschmid associated 173 
the shift in DC-potential with reduced food intake in healthy subjects, suggesting intravenous 174 
detemir had an enhanced anorexigenic impact on the central nervous system that controls 175 
nutrient uptake (11). A lower intake of energy with detemir than with NPH has also been 176 
reported further supporting reduced food intake as a potential mechanism for the weight 177 
sparing effect (1). Finally, the vagus nerve is the most important link between the gut, 178 
pancreas and liver to the brain and appears to be involved in the control of food intake (12). 179 
The indirect action of insulin on the hypothalamus and interaction with hepatic glucose 180 
production is of interest. 181 
 182 
In conclusion, in people with type1 diabetes, clinically relevant doses of subcutaneous 183 
detemir exerts stronger effects on brain function and seems to have a tissue selective action 184 
with preference for brain tissue compared with peripheral tissues. This may be an important 185 
mechanism behind the limitation of weight gain.  186 
 187 
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Figure 1 legend.  The mean DC-potential averaged across all subjects and all 243 
electrodes and plotted against time relative to the subcutaneous injection. Data were 244 
expressed as means and standard errors of means (SEM). 245 
 246 
 247 
Table 1. DC-Potentials (mV). The effect of treatment and treatment by time interaction (time as a 248 
repeated measure) for each channel during the euglycaemic clamp period and hyperglycaemia period.  249 
 250 
 F3: left 
frontal 
F4: right 
frontal 
C3: left 
central 
C4: right 
central 
FC3: left 
frontocentral 
FC4: right 
frontocentral 
Euglycaemic clamp (90-210 minutes) 
Treatment 
interaction 
F(1,20) 
=25.6, 
p<0.0001* 
F(1,31) 
=23.8, 
p<0.0001* 
F(1,28) 
=1.02, 
p=0.32 
F(1,23) 
=0.49, 
p=0.49 
F(1,17)        
= 0.66,  
p =0.43 
F(1,23)        
= 7.40, 
p=0.01* 
Treatment 
by time 
interaction 
F(7,24)   
=3.67, 
p<0.008* 
F(7,25) 
=5.26, 
p<0.008* 
F(7,27) 
=1.84, 
p=0.12 
F(7,25) 
=2.77, 
p=0.03* 
F(7,22)        
= 2.84, 
p=0.03* 
F(7,27)        
= 2.67, 
p=0.03* 
Hyperglycaemic period (210 -300 minutes) 
Treatment 
interaction 
F(1,1) 
=0.56, 
p=0.60 
F(1,14)     
= 0.16, 
p=0.70 
F(1,5)  
=0.59, 
p=0.48 
F(1,12)= 
0.40, 
p=0.54 
F(1,11)         
= 1.51, 
p=0.25 
F(1,11)        
= 1.15, 
p=0.31 
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Treatment 
by time 
interaction 
F(3,1) 
=0.38, 
p=0.80 
F(3,16) 
=1.60, 
p=0.23 
F(3,10)  
=3.69, 
p=0.05* 
F(3,14) 
=5.95, 
p=0.008* 
F(3,13)        
= 1.14, 
p=0.37 
F(3,13)        
= 1.46, 
p=0.27 
 251 
Supplemental Figure 1 legend. Plasma glucose concentration plotted against time in 252 
the clamp protocol. Closed circles represent insulin detemir and open circles represent 253 
NPH insulin. Values are mean±SEM, n=12 254 
 255 
 256 
 257 
Supplemental Figure 2 legend. Glucose rate of appearance (Ra) and glucose rate of 258 
disappearance (Rd) plotted against time. Closed circles represent insulin detemir and 259 
open circles represent NPH insulin. Values are mean±SEM, n=12 260 
 261 
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 262 
Supplemental Figure 3 legend. Glycerol concentration and glycerol rate of production 263 
(Ra) plotted against time. Closed circles represent insulin detemir and open circles 264 
represent NPH insuln. Values are mean±SEM, n=12 265 
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Inclusion Criteria Exclusion Criteria 
Type 1 diabetes greater than 12 months Proliferative retinopathy that had required 
treatment within the preceding 3 months 
BMI less than 35 Impaired hepatic function 
Over 18 years of age Impaired renal function 
HbA1c of greater or equal to 37mmol/mol 
(5.5%) and less than 75mmol/mol (9%) 
Impaired cardiac function 
 14 
Insulin administered via multiple daily 
dosing regime or continuous 
subcutaneous insulin infusion. 
People with uncontrolled hypertension 
defined as a blood pressure greater than 
160/90mmHg 
 Mental incapacity 
 Pregnancy 
 suspected allergy to the trial products. 
 
 267 
Supplement table 1. Inclusion and exclusion criteria 268 
 269 
Supplement Table 2. DC potentials (mV): Treatment by time interaction for channel F3 and F4 during 270 
the euglycaemic clamp (120 – 210 mins) and hyperglycaemia period (210 – 270 mins). 271 
 272 
Time (minutes) Difference in 
LS means 
(mV) 
Std Error Confidence Intervals 
Euglycaemic clamp period: F3 (Left frontal) 
120 -8.143 2.95 (-14.414, -1.872) 
150 -7.523 3.82 (-15.613, 0.567) 
180 -7.646 4.33 (-16.794, 1.501) 
210 -7.504 4.96 (-17.967, 2.958) 
Hyperglycaemia period: F3 (Left frontal) 
240 4.295 5.15 (-10.177, 18.766) 
270 4.426 5.53 (-9.725, 18.577) 
Euglycaemic clamp period: F4 (Right frontal) 
120  -3.278 4.16 (-12.311, 5.755) 
150 -2.613 4.68 (-12.704, 7.477) 
180 -1.565 5.147 (-12.624, 9.494) 
210  -1.059 5.58 (-13.020, 10.902) 
Hyperglycaemia period: F4 (Right frontal) 
240  0.797 5.03 (-9.975, 11.570) 
270  1.566 5.31 (-9.806, 12.939) 
 273 
Supplement Table 3.  274 
AC-Spectral Power (mV). The treatment and treatment by channel interaction (channel and 275 
time were repeated measures) for combined channels at each band frequency during the 276 
euglycaemic clamp period.  277 
 278 
 Low 
Delta 
0-0.5Hz 
Delta 
0.5-
4.5Hz 
Theta  
5-7.5Hz 
Alpha  
8-11.5 
Hz 
Sigma1 
12-
14.5Hz 
Beta-1 
15-
19.5Hz 
Beta-2 
20-
24.5Hz 
Beta-3 
25-
31.5.Hz 
‘Eyes open’ PERIOD  
 15 
Treatment 
effect 
F(1,41)  
= 0.11, 
p=0.74 
F(1,42)
= 0.03, 
p=0.86 
F(1,39) 
=4.87, 
P=0.03 
F(1,38) 
=3.10, 
P=0.08 
F(1,36) 
=0.26,   
P=0.61 
F(1,36) 
=0.39,    
P=0.53 
F(1,39)
=1.61,  
P=0.21 
F(1,34) 
=0.76,      
P=0.39 
Treatment by 
channel 
interaction 
F(10,38)
= 1.85, 
p=0.08 
F(10,38) 
=0.86, 
P=0.57    
F(10,41) 
=1.19, 
P=0.33 
F(10,40) 
=0.65, 
P=0.76 
F(10,38) 
=0.30, 
P=0.98 
F(10,41) 
=0.43,   
P=0.93 
F(10,42)
=0.67, 
P=0.75 
F(1,34)    
= 0.63,     
P=0.43 
‘Eyes closed’ PERIOD  
Treatment 
effect 
F(1,36)  
= 0.57, 
P=0.46 
F(1,32)
= 0.49. 
P=0.47 
F(1,35) 
=2.48, 
P=0.12 
F(1,45) 
=0.59, 
P=0.44 
F(1,36) 
=0.75,   
P=0.39 
F(1,35) 
=0.25,    
P=0.61 
F(1,36) 
=0.26,  
P=0.61 
F(1,36) 
=0.55,      
P=0.93 
Treatment by 
channel 
interaction 
F(10,41)
= 0.62, 
P=0.79 
F(10,41) 
=0.27 
P=0.98    
F(10,41) 
=0.71, 
P=0.71 
F(10,39) 
=1.04, 
P=0.43 
F(10,40) 
=0.61, 
P=0.80 
F(10,42) 
=1.37,   
P=0.22 
F(10,41)
=1.80, 
P=0.09 
F(1,41)    
= 1.55,     
P=0.16 
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